Johnny Andrew’s Post

What are the top takeaways from Day 2 of the PDA - Parenteral Drug Association #visualinspection Forum? (Bonus points for identifying the happy guys in this photo.)

NMR Coupled with Multivariate Data Analysis for Monitoring the Degradation of a Formulated Therapeutic Monoclonal Antibody The function of a protein is directly coupled to its higher-order structure (HOS). Deviations in this critical quality attribute (CQA) may be linked to a decrease in the efficacy and/or safety of the final therapeutic product. High-resolution nuclear magnetic resonance (NMR) spectroscopy has been recently highlighted for protein HOS characterization, thanks to its ability to capture small changes at the molecular and structural levels (primary, secondary, tertiary and quaternary). The present study was carried out to demonstrate the ability of NMR (1D 1H and 2D 1H-13C experiments) coupled with multivariate data analysis (PCA and PLS regression) to monitor the degradation of a formulated mAb-like protein and for the simultaneous quantification of related CQAs, i.e., potency, purity and impurities (aggregates and fragments). The results indicate that this approach could be applied to mitigate product quality risks during development, manufacturing and stability studies of mAb therapeutics. https://lnkd.in/gZhF6uwm #aspenalert #biotech #bioprocess

🚀 A New Breakthrough in Drug Development: Elucidating Chiral Structures with NMR Spectroscopy Researchers from the Karlsruhe Institute of Technology (KIT) and Voxalytic GmbH have made an exciting advancement in nuclear magnetic resonance (NMR) spectroscopy, allowing for the first-time direct measurement of molecular chirality. This development could revolutionize drug discovery, as understanding a molecule’s chiral structure is crucial for ensuring its safety and effectiveness in pharmaceuticals. The ability to determine whether a molecule is left-handed or right-handed, known as its chirality, plays a critical role in biochemical reactions. History reminds us how devastating mistakes in chirality can be—the case of Thalidomide, which led to birth defects in the 1960s, underscores the importance of this discovery. This newly patented method, developed under the leadership of Professor Jan Korvink at KIT, is expected to become a standard tool in the pharmaceutical industry, potentially accelerating drug screening and the search for safe, effective active ingredients. What does this mean for the future of drug development? This innovation could drastically cut down the time it takes to develop new drugs by offering a precise, atomic-level view of molecular structures. #PharmaceuticalInnovation #DrugDevelopment #Chirality #NMRspectroscopy #ChemicalResearch #Enantiomers #AdvancedMaterials #MolecularStructure #BiotechBreakthrough #KarlsruheInstituteOfTechnology #KIT #NIT #IIT #Voxalytic #HealthcareInnovation #DrugChemistry #MedicinalChemistry #Biotechnology #MolecularBiology #Nanotechnology #StemCellResearch #DrugDiscovery #Pharmacology #Biopharmaceuticals #StructuralBiology #DrugScreening #Chemistry #OrganicChemistry #AnalyticalChemistry

Dr. Eliot Siegel of the University of Maryland says there have been many new developments in radiopharmaceuticals over the past year, including increased venture capital investments and pharma acquisitions. Siegel says researchers are studying thousands of molecules that could lead to many more radiopharmaceutical therapies. One of the biggest trends is the development of alpha radiopharmaceuticals that may be more effective and have advantages over beta therapies, he adds.

The Theranostics market is Projected to Grow at a CAGR of 15.5% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞- https://lnkd.in/dYZ_Tegs The global theranostics market in terms of revenue was estimated to be worth $2.1 Billion in 2023 and is poised to reach $4.3 Billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028. 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐬 𝐈𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US), etc 𝐎𝐭𝐡𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Advanced Accelerator Applications Bayer GE HealthCare Siemens Healthineers Cardinal Health Philips Canon Inc. Curium Pharma Lantheus NorthStar Medical Radioisotopes, LLC Eckert & Ziegler SE Pharmalogic Eczacıbaşı-Monrol Nuclear Products Acrotech Biopharma Inc Thermo Fisher Scientific Global Medical Solutions SHINE Technologies Isotopia Molecular Imaging ltd Institute of Isotopes Co. Ltd. China Isotope & Radiation Corp Yantai Dongcheng Pharmaceutical Group Co., Ltd AtomVie Global Radiopharma Inc. ABX advanced biochemical compounds GmbH Telix Pharmaceuticals Limited Blue Earth Diagnostics Sofie Biosciences, Inc. Theragnostics

The Theranostics market is Projected to Grow at a CAGR of 15.5% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞:-https://lnkd.in/d6W9bTeW The global theranostics market in terms of revenue was estimated to be worth $2.1 Billion in 2023 and is poised to reach $4.3 Billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028. 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐬 𝐈𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US), etc 𝐎𝐭𝐡𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Advanced Accelerator Applications Bayer GE HealthCare Siemens Healthineers Cardinal Health Philips Canon Inc. Curium Pharma Lantheus NorthStar Medical Radioisotopes, LLC Eckert & Ziegler SE Pharmalogic Eczacıbaşı-Monrol Nuclear Products Acrotech Biopharma Inc Thermo Fisher Scientific Global Medical Solutions SHINE Technologies Isotopia Molecular Imaging ltd Institute of Isotopes Co. Ltd. China Isotope & Radiation Corp Yantai Dongcheng Pharmaceutical Group Co., Ltd AtomVie Global Radiopharma Inc. ABX advanced biochemical compounds GmbH Telix Pharmaceuticals Limited Blue Earth Diagnostics Sofie Biosciences, Inc. Theragnostics

Pepticom designs (and not randomly designs) highly stable peptide drug that can remain active in the body for longer periods, increasing their bioavailability. With AI algorithms and reinforcement learning backed by laboratory synthesis, Pepticom can discover the most effective peptide sequences for specific targets, in expedited process and timeline. We are excited to be part of your journey to revolutionize peptide development with unprecedented efficiency and precision and scalability.

SFBN Feed: GE HealthCare to take over Japanese radiopharmaceutical venture https://lnkd.in/gEgMJS2m GE HealthCare plans to take full control of Nihon Medi-Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. The company had previously split ownership of the Tokyo-based nuclear medicine outfit down the middle with Sumitomo [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐫𝐞𝐭𝐫𝐨-𝐢𝐧𝐯𝐞𝐫𝐬𝐨 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐚𝐧𝐝 𝐭𝐡𝐞𝐢𝐫 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲? Peptide drugs, though often potent in their biological activities, often face hurdles such as protease degradation that reduces their half life and bioavailability. However, retro-inverso #peptides, a kind of non canonical peptides recently explored in a new article on #drugdiscovery, are a promising solution for drug developers. Retro-inverso peptides are a type of peptidomimetic using D-amino acids (retro isomers) and inverting the primary sequence of the original peptide (inverted). This dual modification creates a stable version of the peptide that is not easily recognized and broken down by biological systems. As retro-inverso peptides are more resistant to proteolytic degradation they can remain active in the body for longer periods increasing their bioavailabiity, while their unique structure can enhance binding affinity and specificity to their targets. This makes them highly interesting in drug discovery. Yet their implementation can be intricate and time-consuming. Fortunately, artificial intelligence can facilitate and expedite the process, revolutionizing peptide development. AI algorithms can analyze vast datasets of peptide sequences and structure-function relationships to design the most effective peptide sequences for specific targets, with enhanced peptide durability and absorption in the body. For example, by leveraging machine learning techniques, researchers can design shorter versions of retro-inverso peptides with optimized biological properties. AI-enabled virtual screening platforms can also expedite the selection of retro-inverso peptidomimetics for experimental validation. By predicting binding affinities and interactions with target receptors, AI algorithms narrow down the pool of candidates, streamlining the selection process and reducing the need for extensive experimental testing. Last but not least, AI algorithms can optimize experimental design and data analysis for phage binding assays, accelerating the identification of retro-inverso peptidomimetics that effectively compete with native peptides for receptor binding. Machine learning models can analyze assay results in real-time, guiding researchers towards promising candidates for further characterization. Integrating AI into the retroinversion pipeline, it is clear, will revolutionize peptidomimetic development and provide unprecedented efficiency and precision, and scalability. Read the full article on peptidomimetic development here >> https://lnkd.in/d9ykxYj8 #AI

Siemens Healthineers has completed the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis, expanding its production and distribution of PET radiopharmaceuticals. The deal adds 13 European manufacturing sites to Siemens' PETNET Solutions, enhancing delivery capabilities. The PET diagnostics market in the covered regions is expected to triple by 2033